CCIA
ICPT

Campbell & Co Investment Adviser’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-49,122
Closed -$685K – 1056
2022
Q3 		$685K Buy
+49,122
New +$791K 0.16% 219
2021
Q3 		– Sell
-38,034
Closed -$760K – 828
2021
Q2 		$760K Buy
+38,034
New +$754K 0.31% 75
2019
Q3 		– Sell
-5,174
Closed -$412K – 807
2019
Q2 		$412K Buy
+5,174
New +$463K 0.19% 199

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Campbell & Co Investment Adviser's ICPT Position: Q4 2022 in Review

Campbell & Co Investment Adviser sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2022, closing a stake of 49,122 shares — an estimated $685K sold.

Campbell & Co Investment Adviser first reported a position in ICPT in Q2 2019 and held it in 3 quarters. The position peaked at $760K in Q2 2021. 144 funds tracked by Wall St. Rank hold ICPT as of Q4 2022.

  • Campbell & Co Investment Adviser reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 49,122 Intercept Pharmaceuticals, Inc. shares in Q4 2022, an estimated $685K.
  • Campbell & Co Investment Adviser first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2019 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Intercept Pharmaceuticals, Inc. position peaked at $760K in Q2 2021.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2022.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2022, filed 14 Feb 2023.